XANOMELINE TARTRATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H23N3OS.C4H6O6
Molecular Weight	431.504
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCOC1=NSN=C1C2=CCCN(C)C2

InChI

InChIKey=SJSVWTMVMBGIHQ-LREBCSMRSA-N

InChI=1S/C14H23N3OS.C4H6O6/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12;5-1(3(7)8)2(6)4(9)10/h8H,3-7,9-11H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1

HIDE SMILES / InChI

Molecular Formula	C4H6O6
Molecular Weight	150.0868
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C14H23N3OS
Molecular Weight	281.417
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16002459 | https://www.ncbi.nlm.nih.gov/pubmed/12212779

Xanomeline (LY-246,708) is an orthosteric muscarinic acetylcholine receptor (mAChR) agonist, often referred to as M1/M4-preferring. It is also known to act as a M5 receptor antagonist. Xanomeline was studied in clinical trials phase I in schizophrenia. In Phase II clinical trials in Alzheimer’s patients, xanomeline significantly improved several measures of cognitive function, yet produced unwanted side effects that limited patient compliance. The side effects seem to be associated with rapid metabolism of the alkyloxy side chain following oral administration, resulting in a nonselective, yet active compound with limited therapeutic utility. Despite a second Phase II clinical trial with a patch formulation, the liabilities of xanomeline still outweigh its benefits.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor M4 87 Target ID: P08173 Gene ID: 1132.0 Gene Symbol: CHRM4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16002459	Agonist 2752
Muscarinic acetylcholine receptor M1 168 Target ID: P11229 Gene ID: 1128.0 Gene Symbol: CHRM1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16002459	Agonist 2752
Muscarinic acetylcholine receptor M5 63 Target ID: P08912 Gene ID: 1133.0 Gene Symbol: CHRM5 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16002459	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 278 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28141924	Primary		Phase II 1147	Unknown Approved Use Unknown
Schizophrenia 305 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28141924	Primary		Phase I 438	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
8.95 ng/mL EXPERIMENT https://link.springer.com/chapter/10.1007/978-1-4615-8149-9_40	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	XANOMELINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: UNKNOWN
13.81 ng/mL EXPERIMENT https://link.springer.com/chapter/10.1007/978-1-4615-8149-9_40	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	XANOMELINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: UNKNOWN
4.13 ng/mL EXPERIMENT https://link.springer.com/chapter/10.1007/978-1-4615-8149-9_40	75 mg 2 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	XANOMELINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
42.8 ng × h/mL EXPERIMENT https://link.springer.com/chapter/10.1007/978-1-4615-8149-9_40	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		XANOMELINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: UNKNOWN
65.8 ng × h/mL EXPERIMENT https://link.springer.com/chapter/10.1007/978-1-4615-8149-9_40	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		XANOMELINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.96 h EXPERIMENT https://link.springer.com/chapter/10.1007/978-1-4615-8149-9_40	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		XANOMELINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: UNKNOWN
4.56 h EXPERIMENT https://link.springer.com/chapter/10.1007/978-1-4615-8149-9_40	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		XANOMELINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	Other AEs: Sweating, Nausea... Other AEs: Sweating (75.9%) Nausea (51.7%) Vomiting (42.5%) Dyspepsia (24.1%) Chills (36.8%) Chest pain (11.5%) increased salivation (24.1%) Syncope (12.6%) Fecal incontinence (6.9%) Nausea and vomiting (8%) Dysphagia (6.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/9109749

AEs

AE	Significance	Dose	Population
Chest pain	11.5%	225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749
Syncope	12.6%	225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749
Dyspepsia	24.1%	225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749
increased salivation	24.1%	225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749
Chills	36.8%	225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749
Vomiting	42.5%	225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749
Nausea	51.7%	225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749
Dysphagia	6.9%	225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749
Fecal incontinence	6.9%	225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749
Sweating	75.9%	225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749
Nausea and vomiting	8%	225 mg 1 times / day multiple, oral Highest studied dose Dose: 225 mg, 1 times / day Route: oral Route: multiple Dose: 225 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9109749	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9109749

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	substrate 1193	substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2C8 810 FMO1 25 FMO3 77 CYP2C19 1119 CYP1A2 1197 CYP2A6 626 CYP2E1 729 CYP2B6 776

Drug as victim

Target	Modality	Activity
CYP2A6 626	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10497134/	likely
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10497134/	likely
CYP2E1 729	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10497134/	likely
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10497134/	minor
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10497134/	minor
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10497134/	minor
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10497134/	minor
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10497134/	yes
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10497134/	yes
FMO1 25	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10497134/	yes
FMO3 77	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10497134/	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY114854	https://www.001chemical.com/chem/search?q=DY114854
1PlusChem LLC	1P001GAT	https://www.1pchem.com/search?query=1P001GAT
AK Scientific	4161AH	https://aksci.com/item_detail.php?cat=4161AH
AK Scientific	G849	https://aksci.com/item_detail.php?cat=G849
Ambeed	A114713	http://www.ambeed.com/search/Search.html?keyword=A114713
Angene	AGN-PC-0WHAOK	http://www.angenechemical.com/productshow/AGN-PC-0WHAOK.html
AstaTech	C72296	http://astatechinc.com/CPSResult.php?CRNO=C72296
BLD Pharm	BD448272	http://www.bldpharm.com/search/Search.html?keyword=BD448272
BOC Sciences	131986-45-3	http://www.bocsci.com/description.asp?cas=131986-45-3
BOC Sciences	141064-23-5	http://www.bocsci.com/description.asp?cas=141064-23-5
Cayman Chemical	10790	http://www.caymanchem.com/app/template/Product.vm/catalog/10790
Chem Scene	CS-2124	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-2124
Combi-Blocks	QJ-7407	http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-7407
Combi-Blocks	QV-5368	http://www.combi-blocks.com/cgi-bin/find.cgi?QV-5368
eMolecules	29703210	https://orderbb.emolecules.com/search/#?query=29703210
eMolecules	300436560	https://orderbb.emolecules.com/search/#?query=300436560
eMolecules	44471106	https://orderbb.emolecules.com/search/#?query=44471106
eNovation Chemicals	D515415	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D515415&searchbtn.x=0&searchbtn.y=0
KeyOrganics	DS-15663	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=DS-15663
Lab Network	LN00198999	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00198999
Lab Network	LN01315811	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01315811
Matrix Scientific	97008	http://www.matrixscientific.com/097008.html
mcule	MCULE-2400708987	https://mcule.com/MCULE-2400708987/
mcule	MCULE-8362695048	https://mcule.com/MCULE-8362695048/
MedChem Express	HY-13410	https://www.medchemexpress.com/search.html?q=HY-13410&ft=&fa=&fp=
Molcore	MC114854	http://www.molcore.com/CatMC114854.html
Molnova	M11712	https://www.molnova.com/en/serch-list.html?keywords=M11712
MolPort	MolPort-023-276-854	https://www.molport.com/shop/molecule-link/MolPort-023-276-854
MolPort	MolPort-023-334-334	https://www.molport.com/shop/molecule-link/MolPort-023-334-334
MuseChem	I012049	https://www.musechem.com/product/I012049.html
ShangHai Biochempartner	BCP11070	http://www.biochempartner.com/search_BCP11070
Tetrahedron	TS34352	http://www.thsci.com/search.do?q=TS34352
Tocris	3569	https://www.tocris.com/search.php?Type=QuickSearch&Value=3569
Toronto Research Chemicals	H298183	https://www.trc-canada.com/product-detail/?CatNum=H298183
Vesino Industrial Co Ltd	VP14766	http://www.vsnchem.com/search.do?a=s&psize=20&q=VP14766
Wonderchem	WD052ZH	http://www.wonder-chem.com/search.html?text=WD052ZH

PubMed

Title	Date	PubMed
The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.	2011-10	21211109
Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold.	2011-07-14	21682298
Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor.	2010-12-23	21203415
M1 muscarinic receptor for the development of auditory cortical function.	2010-10-22	20964868
Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics.	2010-10	20676613
The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.	2010-10	20660086
Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.	2010-07	20571970
Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms.	2010-06-18	20406819
The antipsychotic potential of muscarinic allosteric modulation.	2010-05	20520852
A novel derivative of xanomeline improves fear cognition in aged mice.	2010-04-05	20178835
Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors.	2010-03-11	20158205
Update on the pharmacological treatment of Alzheimer's disease.	2010-03	20808547
Attenuation of cocaine's reinforcing and discriminative stimulus effects via muscarinic M1 acetylcholine receptor stimulation.	2010-03	19996296
Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice.	2010-02	20013114
Prefrontal cortex and reversion of atropine-induced disruption of the degraded contingency effect by antipsychotic agents and N-desmethylclozapine in rats.	2010-02	19531280
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.	2010	20954431
Confocal Analysis of Cholinergic and Dopaminergic Inputs onto Pyramidal Cells in the Prefrontal Cortex of Rodents.	2010	20589096
Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors.	2009-12-28	20038295
Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands.	2009-12-02	19951444
Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.	2009-12	20514210
Immediate and delayed consequences of xanomeline wash-resistant binding at the M3 muscarinic receptor.	2009-06	19082883
Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists.	2009-03-01	19168056
Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.	2009-01-28	19111716
Reduction in muscarinic M1-mediated hypercholinergic state and beneficial cognitive effects of muscarinic agonists in schizophrenia.	2009-01	19122018
Antipsychotic properties of muscarinic drugs.	2009-01	19122017
Mechanisms of M3 muscarinic receptor regulation by wash-resistant xanomeline binding.	2009	19401618
Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine.	2008-12	18586865
Enhancement of memory function in aged mice by a novel derivative of xanomeline.	2008-11	18936783
Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine.	2008-10-31	18771666
Role of the central cholinergic system in the therapeutics of schizophrenia.	2008-09	19506725
A novel derivative of xanomeline improved memory function in aged mice.	2008-08	18668154
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.	2008-08	18593778
Muscarinic acetylcholine receptors: new potential therapeutic targets in antinociception and in cancer therapy.	2008-06	18537768
Pharmacological assessment of m1 muscarinic acetylcholine receptor-gq/11 protein coupling in membranes prepared from postmortem human brain tissue.	2008-06	18322150
Role of M1 receptor in the locomotion behavior of the African mole-rat (Cryptomys sp).	2008-03	18431815
Synthesis and evaluation of xanomeline analogs--probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor.	2008-02-01	17977730
Importance and prospects for design of selective muscarinic agonists.	2008	18481916
Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.	2007-12	17855477
Allosteric modulators of class B G-protein-coupled receptors.	2007-09	19305799
Allosteric modulation of muscarinic acetylcholine receptors.	2007-09	19305798
Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain.	2007-07	17446301
Effects of muscarinic agonists in the guinea-pig prostate.	2007-04	17391281
Evaluation of [18F]fluoroxanomeline {5-{4-[(6-[18F]fluorohexyl)oxy]-1,2,5-thiadiazol-3-yl}-1-methyl-1,2,3,6-tetrahydropyridine} in muscarinic knockout mice.	2007-02	17307122
Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor.	2006-12-13	17052840
Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.	2006-08	16709648
Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.	2006-08	16675658
Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor.	2005-10	16002459
The evaluation of cognitive function in the dementias: methodological and regulatory considerations.	2003-03	22033730
Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.	1998-12	9884068
On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.	1998-06	9614217

Patents

Sample Use Guides

In Vivo Use Guide

Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Placebo, TID

Route of Administration: Oral

In Vitro Use Guide

CHO cells, stably expressing the human M5 muscarinic acetylcholine receptor were incubated for 1 h at 37°C in the absence or presence of xanomeline (1, 10, or 30 μM). Further experiments were designed to assess whether xanomeline, a partial agonist, can act as an antagonist to a full agonist at the M5 receptor. Cells were incubated for 1 h with 3 μM carbachol in the absence or in the presence of increasing concentrations of xanomeline. Xanomeline was able to antagonize the ability of carbachol to stimulate PI production in a concentration-dependent manner down to the level of maximal receptor activation by xanomeline alone.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:12:29 GMT 2025` Edited by `admin` on `Mon Mar 31 18:12:29 GMT 2025`
Record UNII	B80W7AUT8R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

XANOMELINE (+)-L-HYDROGEN TARTRATE

Preferred Name

English

XANOMELINE TARTRATE

Official Name

English

3-(4-(HEXYLOXY)-1,2,5-THIADIAZOL-3-YL)-1,2,5,6-TETRAHYDRO-1-METHYLPYRIDINE (-)-(+)-TARTRATE (1:1)

Systematic Name

English

COBENFY COMPONENT XANOMELINE TARTRATE

Brand Name

English

PYRIDINE, 3-(4-(HEXYLOXY)-1,2,5-THIADIAZOL-3-YL)-1,2,5,6-TETRAHYDRO-1-METHYL-, (R-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE (1:1)

Systematic Name

English

LY-246708 TARTRATE

Code

English

Xanomeline tartrate [WHO-DD]

Common Name

English

XANOMELINE (+)-L-HYDROGEN TARTRATE [MI]

Common Name

English

XANOMELINE TARTRATE [USAN]

Common Name

English

LY246708 TARTRATE

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C47796